secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001628280-25-038855
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo reports positive Fabry gene therapy data, Q2 net loss narrows to $20M
-----------------------------------------------------------------------------

- Positive topline from registrational STAAR study: mean annualized eGFR slope +1.965 at 52 weeks across all 32 dosed Fabry patients; FDA agrees as primary basis for accelerated approval.
- BLA submission for isaralgagene civaparvovec expected as early as Q1 2026; business development for Fabry commercialization ongoing.
- First clinical site initiated for Phase 1/2 STAND study in chronic neuropathic pain; first patient dosing expected fall 2025, preliminary efficacy data Q4 2026.
- Q2 2025 revenue $18.3M (vs $0.3M YoY) driven by Lilly license payment; net loss $20.0M ($0.08 EPS) vs $36.1M ($0.18 EPS) prior year.
- Cash $38.3M as of June 30; raised ~$21M net from equity offering; expects funding into Q4 2025; reaffirms 2025 opex guidance $135-155M GAAP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828025038855/0001628280-25-038855-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828025038855/sgmo-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-038855

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer